Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Sci ; 110(2): 629-638, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30457689

ABSTRACT

Nicotinamide adenine dinucleotide (NAD) exists in an oxidized form (NAD+ ) and a reduced form (NADH). NAD+ plays crucial roles in cancer metabolism, including in cellular signaling, energy production and redox regulation. However, it remains unclear whether NAD(H) pool size (NAD+ and NADH) could be used as biomarker for colon cancer progression. Here, we showed that the NAD(H) pool size and NAD+ /NADH ratio both increased during colorectal cancer (CRC) progression due to activation of the NAD+ salvage pathway mediated by nicotinamide phosphoribosyltransferase (NAMPT). The NAMPT expression was upregulated in adenoma and adenocarcinoma tissues from CRC patients. The NADH fluorescence intensity measured by two-photon excitation fluorescence (TPEF) microscopy was consistently increased in CRC cell lines, azoxymethane/dextran sodium sulfate (AOM/DSS)-induced CRC tissues and tumor tissues from CRC patients. The increases in the NAD(H) pool inhibited the accumulation of excessive reactive oxygen species (ROS) levels and FK866, a specific inhibitor of NAMPT, treatment decreased the CRC nodule size by increasing ROS levels in AOM/DSS mice. Collectively, our results suggest that NAMPT-mediated upregulation of the NAD(H) pool protects cancer cells against detrimental oxidative stress and that detecting NADH fluorescence by TPEF microscopy could be a potential method for monitoring CRC progression.


Subject(s)
Colonic Neoplasms/metabolism , Colonic Neoplasms/pathology , NAD/metabolism , Reactive Oxygen Species/metabolism , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Adenoma/metabolism , Adenoma/pathology , Animals , Cell Line, Tumor , Colon/metabolism , Colon/pathology , Disease Progression , HCT116 Cells , Humans , Mice , Mice, Inbred C57BL , Oxidative Stress/physiology , Up-Regulation/physiology
2.
Sci Rep ; 8(1): 17717, 2018 12 07.
Article in English | MEDLINE | ID: mdl-30531928

ABSTRACT

15-hydroxyprostaglandin dehydrogenase (15-PGDH), the rate-limiting enzyme in prostaglandin E2 degradation, is decreased in gastric cancers and microRNA (miR)-21 is one of the regulators. We investigated the expression and regulation of 15-PGDH in eary gastric carcinogenesis utilizing endoscopic submucosal dissection (ESD) and gastric cancer cell lines. Expression of 15-PGDH and cyclooxygenase-2 as well as the promoter methylation of 15-PGDH were evaluted. CRISPR, miR-21 transfection, proliferation and apoptosis assays were also done. We observed significant decreases in 15-PGDH expression but no promoter methylation was detected in any ESDs. 15-PGDH suppression by CRISPR induced enhanced growth kinetics. miR-21, which was detected in high level in gastric tumors from the TGCA data, caused increased proliferation, decreased apoptosis. miR-21 overexpression was confirmed with CISH and RT-PCR in the ESDs. Loss of 15-PGDH occurs at the very early stage of gastric adenocarcinoma by miR-21. H. pylori infection may affect miR-21 up regulation. Maintaining 15-PGDH enzyme activity could be a new strategic measure in preventing gastric cancer especially tubular adenocarcinoma.


Subject(s)
Adenocarcinoma/genetics , Hydroxyprostaglandin Dehydrogenases/genetics , MicroRNAs/genetics , Stomach Neoplasms/genetics , Apoptosis/genetics , Cell Line, Tumor , Cell Proliferation/genetics , Clustered Regularly Interspaced Short Palindromic Repeats/genetics , Cyclooxygenase 2/genetics , Dinoprostone/genetics , Gene Expression Regulation, Enzymologic/genetics , Gene Expression Regulation, Neoplastic , Helicobacter Infections/genetics , Humans , Methylation , Promoter Regions, Genetic/genetics , Prospective Studies , Retrospective Studies , Transfection/methods
3.
Gastroenterology ; 152(3): 616-630, 2017 02.
Article in English | MEDLINE | ID: mdl-27864128

ABSTRACT

BACKGROUND & AIMS: Prostaglandin E2 (PGE2) is mediator of inflammation that regulates tissue regeneration, but its continual activation has been associated with carcinogenesis. Little is known about factors in the PGE2 signaling pathway that contribute to tumor formation. We investigated whether yes-associated protein 1 (YAP1), a transcriptional co-activator in the Hippo signaling pathway, mediates PGE2 function. METHODS: DLD-1 and SW480 colon cancer cell lines were transfected with vectors expressing transgenes or small hairpin RNAs and incubated with recombinant PGE2, with or without pharmacologic inhibitors of signaling proteins, and analyzed by immunoblot, immunofluorescence, quantitative reverse-transcription polymerase chain reaction, transcriptional reporter, and proliferation assays. Dextran sodium sulfate (DSS) was given to induce colitis in C57/BL6 (control) mice, as well as in mice with disruption of the hydroxyprostaglandin dehydrogenase 15 gene (15-PGDH-knockout mice), Yap1 gene (YAP-knockout mice), and double-knockout mice. Some mice also were given indomethacin to block PGE2 synthesis. 15-PGDH knockout mice were crossed with mice with intestine-specific disruption of the salvador family WW domain containing 1 gene (Sav1), which encodes an activator of Hippo signaling. We performed immunohistochemical analyses of colon biopsy samples from 26 patients with colitis-associated cancer and 51 age-and sex-matched patients with colorectal cancer (without colitis). RESULTS: Incubation of colon cancer cell lines with PGE2 led to phosphorylation of cyclic adenosine monophosphate-responsive element binding protein 1 and increased levels of YAP1 messenger RNA, protein, and YAP1 transcriptional activity. This led to increased transcription of the prostaglandin-endoperoxide synthase 2 gene (PTGS2 or cyclooxygenase 2) and prostaglandin E-receptor 4 gene (PTGER4 or EP4). Incubation with PGE2 promoted proliferation of colon cancer cell lines, but not cells with knockdown of YAP1. Control mice developed colitis after administration of DSS, but injection of PGE2 led to colon regeneration in these mice. However, YAP-knockout mice did not regenerate colon tissues and died soon after administration of DSS. 15-PGDH-knockout mice regenerated colon tissues more rapidly than control mice after withdrawal of DSS, and had faster recovery of body weight, colon length, and colitis histology scores. These effects were reversed by injection of indomethacin. SAV1-knockout or 15-PGDH-knockout mice did not develop spontaneous tumors after colitis induction, but SAV1/15-PGDH double-knockout mice developed polyps that eventually progressed to carcinoma in situ. Administration of indomethacin to these mice prevented spontaneous tumor formation. Levels of PGE2 correlated with those of YAP levels in human sporadic colorectal tumors and colitis-associated tumors. CONCLUSIONS: PGE2 signaling increases the expression and transcriptional activities of YAP1, leading to increased expression of cyclooxygenase 2 and EP4 to activate a positive signaling loop. This pathway promotes proliferation of colon cancer cell lines and colon tissue regeneration in mice with colitis. Constitutive activation of this pathway led to formation of polyps and colon tumors in mice.


Subject(s)
Adaptor Proteins, Signal Transducing/drug effects , Cell Proliferation/drug effects , Colon/drug effects , Colorectal Neoplasms/genetics , Dinoprostone/pharmacology , Phosphoproteins/drug effects , RNA, Messenger/drug effects , Regeneration/drug effects , Adaptor Proteins, Signal Transducing/genetics , Animals , Carcinogenesis/drug effects , Carcinogenesis/genetics , Case-Control Studies , Cell Cycle Proteins/genetics , Cell Line, Tumor , Cell Proliferation/genetics , Colitis/chemically induced , Colon/metabolism , Cyclooxygenase 2 , Dextran Sulfate/toxicity , Feedback , Fluorescent Antibody Technique , Humans , Hydroxyprostaglandin Dehydrogenases/genetics , Immunoblotting , Immunohistochemistry , MAP Kinase Signaling System , Mice , Mice, Inbred C57BL , Mice, Knockout , NF-kappa B , Phosphoproteins/genetics , Proto-Oncogene Proteins c-akt , RNA, Messenger/metabolism , Receptors, Prostaglandin E, EP4 Subtype , Regeneration/genetics , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction , Up-Regulation , YAP-Signaling Proteins
SELECTION OF CITATIONS
SEARCH DETAIL
...